This finding is important since inhibitors of IL-6, such as tocilizumab and JAK2, such as ruxolitinib, are already in clinical use for the treatment of rheumatoid arthritis and osteomyelofibrosis, respectively. The gene discussed is JAK2; the disease is rheumatoid arthritis.